Stock EVT EVOTEC SE
Add to a list

Evotec SE Share Price

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra
Other stock markets
 10:05:19 16/01/2026 pm IST 		5-day change 1st Jan Change
6.308 EUR -0.28% Intraday chart for Evotec SE +0.35% +15.74%
13/01 Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec RE
08/01 Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies MT

Valuation: Evotec SE

Capitalization 111.86Cr 129.75Cr 104.13Cr 97Cr 180.49Cr 12TCr 194.19Cr 1.2TCr 472.29Cr 5.62TCr 486.57Cr 476.55Cr 21TCr P/E ratio 2025 *
-17x
P/E ratio 2026 * -46.3x
Enterprise value 119.35Cr 138.44Cr 111.1Cr 103.43Cr 192.58Cr 13TCr 207.2Cr 1.28TCr 503.92Cr 5.99TCr 519.15Cr 508.46Cr 22TCr EV / Sales 2025 *
1.53x
EV / Sales 2026 * 1.46x
Free-Float
88.77%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data

Chart: Evotec SE

Dynamic Chart

Latest news: Evotec SE

13/01 Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec RE
08/01 Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies MT
08/01 Evotec Remains in Demand on Tradegate – Funding Secured for Subsidiary DP
07/01 Evotec Continues Upward Trend Following Amgen's Acquisition of Dark Blue DP
07/01 EVOTEC : RBC reiterates its Buy rating ZD
06/01 Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million DJ
05/01 Amgen Inc. acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company and Evotec SE in a transaction valued at $840 million. CI
02/01 Evotec SE Announces Executive Changes CI
17/12 Evotec SE Equity Buyback announced on August 6, 2024, has expired. CI
09/12 Sources: Novo Nordisk Group Holding reduces stake in Evotec DP
09/12 Evotec secondary ABB priced at EUR 5.10 per share, bookrunner says RE
09/12 Bookrunner says Evotec secondary ABB books are closed RE
08/12 Sandoz Concludes Purchase of Evotec's Biologics Platform MT
More news

Last Transcript: Evotec SE

Logo Evotec SE
Evotec SE, Q3 2025 Earnings Call, Nov 05, 2025
05/11
More transcripts

Analysts' recommendations: Evotec SE

07/01 EVOTEC : RBC reiterates its Buy rating ZD
12/11 EVOTEC : Receives a Buy rating from RBC ZD
07/11 EVOTEC : Deutsche Bank remains Neutral ZD
06/11 EVOTEC : Deutsche Bank reiterates its Neutral rating ZD
05/11 EVOTEC : RBC keeps its Buy rating ZD
More recommendations

Press Releases: Evotec SE

16/01 Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
16/01 Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
12/01 Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
08/01 Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution EQ
08/01 Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access EQ
More press releases

News in other languages: Evotec SE

16/01 Evotec SE: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
13/01 Evotec SE: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
08/01 Evotec auf Tradegate weiter gefragt - Fördermittel für Tochter
08/01 US-Tochter von Evotec erhält neue Förderung von Gates-Stiftung
08/01 Just – Evotec Biologics erhält Förderung für KI-gestützte Optimierung der Entwicklungsfähigkeit monoklonaler Antikörper zur Verbesserung des bezahlbaren Zugangs
More news

Quotes and Performance

1 day-0.28%
1 week+0.35%
Current month+15.74%
1 month+21.07%
3 months-8.26%
6 months-13.42%
Current year+15.74%
More quotes

Course Extremes

1 week 6.22
Extreme 6.218
 6.73
1 month 5.09
Extreme 5.09
 6.73
Current year 5.38
Extreme 5.384
 6.73
1 year 4.9
Extreme 4.902
 9.33
3 years 4.9
Extreme 4.902
 24.44
5 years 4.9
Extreme 4.902
 45.83
10 years 2.86
Extreme 2.864
 45.83
More quotes

Managers and Directors: Evotec SE

Manager TitleAgeSince
Christian Wojczewski CEO
 Chief Executive Officer - 01/07/2024
Paul Robert Hitchin DFI
 Director of Finance/CFO - 01/03/2025
Cord Dohrmann CTO
 Chief Tech/Sci/R&D Officer 62 01/09/2010
Director TitleAgeSince
Iris Löw-Friedrich CHM
 Chairman 65 15/06/2021
Roland Sackers BRD
 Director/Board Member 58 19/06/2019
Constanze Ulmer-Eilfort BRD
 Director/Board Member 64 01/06/2021
More insiders

ETFs: Evotec SE

Name Varia. Jan 1. Weight AuM
LYXOR MDAX ESG UCITS ETF - EUR ETF Lyxor MDAX ESG UCITS ETF - EUR
-.--%2.59% 0 M€
LYXOR F.A.Z. 100 INDEX (DR) UCITS ETF - EUR ETF Lyxor F.A.Z. 100 Index (DR) UCITS ETF - EUR
-.--%0.21% 0 M€
More ETFs: Evotec SE

Other Biotechnology & Medical Research

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
EVOTEC SE Stock Evotec SE
-0.28%+0.35%-18.45%-65.02% 129.75Cr
LONZA GROUP AG Stock Lonza Group AG
-0.89%+1.01%+2.08%+11.35% 4.89TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.49%-1.95%+20.25%+7.00% 4.05TCr
BEONE MEDICINES AG Stock BeOne Medicines AG
-0.03%+0.09%+64.70%+24.95% 3.74TCr
CELLTRION, INC. Stock Celltrion, Inc.
-0.71%-3.69%+19.43%+35.85% 3.1TCr
REVOLUTION MEDICINES, INC. Stock Revolution Medicines, Inc.
-2.43%+1.38%+201.45%+299.73% 2.33TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
-1.16%+2.67%+81.37%+167.28% 1.72TCr
Average -1.00%+0.17%+52.98%+68.73% 2.85TCr
Weighted average by Cap. -1.02%-0.10%+50.12%+63.36%
See all sector performances

Financials

2025 *2026 *
Net sales 78Cr 91Cr 73Cr 68Cr 126.05Cr 8.22TCr 135.62Cr 836.51Cr 329.84Cr 3.92TCr 339.81Cr 332.82Cr 14TCr 84Cr 97Cr 78Cr 73Cr 135.5Cr 8.84TCr 145.78Cr 899.17Cr 354.55Cr 4.22TCr 365.27Cr 357.75Cr 15TCr
Net income -7.73Cr -8.97Cr -7.2Cr -6.7Cr -12Cr -813.88Cr -13Cr -83Cr -33Cr -388.22Cr -34Cr -33Cr -1.42TCr -2.82Cr -3.27Cr -2.62Cr -2.44Cr -4.54Cr -296.36Cr -4.89Cr -30Cr -12Cr -141.36Cr -12Cr -12Cr -516.18Cr
Net Debt 7.49Cr 8.69Cr 6.97Cr 6.49Cr 12Cr 788.3Cr 13Cr 80Cr 32Cr 376.02Cr 33Cr 32Cr 1.37TCr 11Cr 13Cr 10Cr 9.63Cr 18Cr 1.17TCr 19Cr 118.97Cr 47Cr 557.75Cr 48Cr 47Cr 2.04TCr
More financial data * Estimated data

Company Profile

Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,788
Sector
Biotechnology & Medical Research
Calendar
01/04 - Q4 2025 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
16/26/16 6.308 € -0.28% 4,72,677
15/26/15 6.326 € -1.25% 4,57,525
14/26/14 6.406 € -2.23% 7,08,363
13/26/13 6.552 € +1.36% 5,82,387
12/26/12 6.464 € +2.83% 7,17,020

Delayed Quote Xetra, January 16, 2026 at 10:05 pm IST

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI
AAA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
6.308EUR
Average target price
8.460EUR
Spread / Average Target
+34.12%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. EVT Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition